转移性去势敏感型前列腺癌的管理：从指南到真实世界实践。
The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice.
机构信息
Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
出版信息
Oncologist. 2023 Sep 7;28(9):746-749. doi: 10.1093/oncolo/oyad047.
Abstract
This commentary highlights 2 international studies on real-world treatment trends and patterns among patients with metastatic castration-sensitive and resistant prostate cancer and how interventions targeting physicians and patients can bridge the gap between evidence-based medicine and real-world practice.
摘要
本述评重点介绍了 2 项国际研究，探讨了转移性去势敏感和抵抗性前列腺癌患者的真实世界治疗趋势和模式，以及针对医生和患者的干预措施如何缩小基于证据的医学与真实世界实践之间的差距。
相似文献
1
The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice.转移性去势敏感型前列腺癌的管理：从指南到真实世界实践。
Oncologist. 2023 Sep 7;28(9):746-749. doi: 10.1093/oncolo/oyad047.
2
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.EAU-ESTRO-SIOG 前列腺癌诊治指南。第二部分：复发、转移和去势抵抗性前列腺癌的治疗。
Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.
3
Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive Review.多西他赛治疗转移性前列腺癌的再挑战：全面综述。
Oncol Res Treat. 2020;43(6):299-306. doi: 10.1159/000506693. Epub 2020 May 7.
4
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.转移性去势初治前列腺癌患者的负担，以识别更可能从早期多西他赛治疗中获益的男性：CHAARTED和GETUG-AFU15研究的进一步分析
Eur Urol. 2018 Jun;73(6):847-855. doi: 10.1016/j.eururo.2018.02.001. Epub 2018 Feb 21.
5
Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer.多西他赛剂量强度对转移性去势敏感前列腺癌患者总生存期的影响。
Cancer Chemother Pharmacol. 2020 May;85(5):863-868. doi: 10.1007/s00280-020-04063-7. Epub 2020 Apr 2.
6
Veterans Affairs Prostate Cancer Treatment Sequencing (VAPCaTS): A Real-World Evidence Study of Men with Metastatic Prostate Cancer.退伍军人事务部前列腺癌治疗序列（VAPCaTS）：一项针对转移性前列腺癌男性患者的真实世界证据研究。
Urol Pract. 2021 Jan;8(1):112-118. doi: 10.1097/UPJ.0000000000000166. Epub 2020 May 29.
7
[Metastatic hormone-sensitive prostate cancer].转移性激素敏感性前列腺癌
Bull Cancer. 2015 Jan;102(1):57-64. doi: 10.1016/j.bulcan.2014.12.003. Epub 2015 Jan 8.
8
Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.优化转移性去势抵抗性前列腺癌的抗癌治疗：美国临床肿瘤学会临床实践指南。
J Clin Oncol. 2018 May 20;36(15):1521-1539. doi: 10.1200/JCO.2018.78.0619. Epub 2018 Apr 2.
9
New developments in metastatic prostate cancer therapy.转移性前列腺癌治疗的新进展
Practitioner. 2015 Apr;259(1781):21-4, 2-3.
10
Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.初诊时伴有转移性疾病的新诊断前列腺癌患者的当代管理
Curr Urol Rep. 2018 Aug 13;19(10):79. doi: 10.1007/s11934-018-0835-7.
引用本文的文献
1
Treatment Patterns and Survival Among Veterans With De Novo Metastatic Hormone-Sensitive Prostate Cancer.初发性转移性激素敏感性前列腺癌退伍军人的治疗模式与生存情况
JAMA Netw Open. 2025 May 1;8(5):e259433. doi: 10.1001/jamanetworkopen.2025.9433.
2
Patterns and Frequency of Pathogenic Germline Variants Among Prostate Cancer Patients Utilizing Multi-Gene Panel Genetic Testing.利用多基因检测板进行基因检测的前列腺癌患者中致病种系变异的模式和频率
World J Oncol. 2024 Oct;15(5):801-808. doi: 10.14740/wjon1896. Epub 2024 Jul 18.
本文引用的文献
1
Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study.真实世界中转移性去势抵抗性前列腺癌患者的治疗模式：一项国际研究的结果。
Oncologist. 2023 Sep 7;28(9):e737-e747. doi: 10.1093/oncolo/oyad046.
2
Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study.真实世界中转移性去势敏感性前列腺癌患者的治疗趋势：一项国际研究的结果。
Oncologist. 2023 Sep 7;28(9):780-789. doi: 10.1093/oncolo/oyad045.
3
Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients.商业保险患者中晚期前列腺癌当代治疗的自付费用负担
J Urol. 2022 Nov;208(5):987-996. doi: 10.1097/JU.0000000000002856. Epub 2022 Sep 12.
4
The (R)evolution of Social Media in Oncology: Engage, Enlighten, and Encourage.社交媒体在肿瘤学中的变革：参与、启发和鼓励。
Cancer Discov. 2022 Jul 6;12(7):1620-1624. doi: 10.1158/2159-8290.CD-22-0346.
5
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.恩杂鲁胺可改善转移性去势敏感性前列腺癌患者的生存。
J Clin Oncol. 2022 May 20;40(15):1616-1622. doi: 10.1200/JCO.22.00193. Epub 2022 Apr 14.
6
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.阿比特龙联合泼尼松加至去势治疗和多西他赛用于初治转移性去势敏感性前列腺癌（PEACE-1）：一项采用2×2析因设计的多中心、开放标签、随机3期研究。
Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8.
7
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.达罗他胺与转移性去势敏感性前列腺癌的生存
**注**：这是基于你提供的文本进行的翻译，实际翻译可能会因上下文和语言习惯而有所不同。
N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17.
8
Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.美国真实世界中转移性去势敏感性前列腺癌患者的管理
J Urol. 2021 Dec;206(6):1420-1429. doi: 10.1097/JU.0000000000002121. Epub 2021 Jul 23.
9
Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study.阿帕鲁胺治疗转移性去势敏感性前列腺癌患者的生存分析：随机、双盲、III 期 TITAN 研究的最终生存分析。
J Clin Oncol. 2021 Jul 10;39(20):2294-2303. doi: 10.1200/JCO.20.03488. Epub 2021 Apr 29.
10
What Do Men with Metastatic Prostate Cancer Consider When Making Treatment Decisions? A Mixed-methods Study.转移性前列腺癌男性在做出治疗决策时会考虑哪些因素？一项混合方法研究。
Patient Prefer Adherence. 2020 Oct 14;14:1949-1959. doi: 10.2147/PPA.S271620. eCollection 2020.
Zotero 插件